Lurbinectedin is a drug that has shown promising results in the treatment of various types of cancer. According to the sources provided [1][2][3], it has been tested in combination with other drugs in preclinical and clinical trials.

One study published in the journal Oncotarget [2] investigated the combination of lurbinectedin with doxorubicin, a chemotherapy drug, in treating small cell lung cancer. The study found that the combination of the two drugs had a synergistic effect, meaning that the drugs worked better together than either drug alone.

Another study published in the journal Cancer Research [3] tested the combination of lurbinectedin with cisplatin, another chemotherapy drug, in treating ovarian cancer. The study found that the combination of the two drugs was effective in reducing tumor growth in mice.

Furthermore, according to DrugPatentWatch [1], there are currently several patents that cover the use of lurbinectedin in combination with other drugs, including cisplatin, doxorubicin, and paclitaxel.

In conclusion, the sources suggest that lurbinectedin can be used in combination with other drugs, and that such combinations have shown promising results in preclinical and clinical trials. However, further research is needed to determine the safety and efficacy of these combinations in treating various types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/
[3] https://pubmed.ncbi.nlm.nih.gov/26986199/